Copernicus Group IRB Company Profile

16:43 EDT 23rd March 2018 | BioPortfolio

Copernicus Group IRB was established in July 1996 as an independent institutional review board (IRB or "Board") and operates in compliance with Federal Regulations governing institutional review boards set forth in 21 CFR, 45 CFR and ICH GCP Guidelines. Copernicus Group IRB is also a member of the Consortium of Independent Review Boards (CIRB), which regularly meets with government regulators to review issues of importance to the protection of human subjects involved in clinical research. Copernicus Group IRB has been inspected by the FDA and in July of 2004, Copernicus Group IRB was awarded full accreditation of our Human Research Protection Program by AAHRPP®, The Association for the Accreditation of Human Research Protection Programs, Inc. CGIRB is registered with OHRP as IRB00001313 which complies with all federal regulations pertaining to the protection of human research subjects


118 MacKenan DriveSuite 400
North Carolina
United States of America


Phone: (919) 465-4310
Fax: (919) 465-4311

News Articles [317 Associated News Articles listed on BioPortfolio]

WIRB-Copernicus Group acquires Vigilare International

WIRB Copernicus Group (WCG), a provider of solutions that measurably improve the quality and efficiency of clinical research, announced its acquisition of Vigilare International, a provider of integra...

WIRB-Copernicus Group partners with Veeva Systems

WIRB-Copernicus Group (WCG), a provider of solutions that measurably improve the quality and efficiency of clinical research, is partnering with Veeva Systems to improve the speed and accuracy of ins...

WCG acquires Vigilare International

WIRB Copernicus Group (WCG) has acquired a provider of integrated end-to-end pharmacovigilance and drug safety solutions for the biopharmaceutical and biotech industry, Vigilare International.

WCG acquires pharmacovigilance firm Vigilare

WIRB Copernicus Group (WCG) has expanded its portfolio of companies to include the pharmacovigilance and drug safety solution provider Vigilare International.

Copernicus Plans Liberal Licensing for its Advanced DNA Delivery Technology

Imagine, for a moment, that every drug on the market suddenly didn’t work because of the lack of an adequate delivery system. That’s precisely the situation gene therapy companies find themselves ...

EMRs are robbing physicians of their writing skills

Many physicians have become world famous writers, and in Greek mythology, Apollo was the god of both poetry and medicine. I can personally think of many prominent physician writers I have come across ...

If We Discover Alien Life, Will Humanity Keep Its Cool?

For well over 1,500 years, humanity accepted that Earth was the center of the solar system. After all, the Bible—which was the scientific authority at the time—said this was so. Then along came N...

WCG Announces — Strategies that Inform Investigation Selection and Enhance Enrollment, Free Webinar, January 25, 2018

Clinical trial operators have no choice but to contract with sites. But are they optimizing the opportunity to accelerate study start-up, reduce expenses, and avoid complications? FALLS CHURCH, Va. (P...

PubMed Articles [1831 Associated PubMed Articles listed on BioPortfolio]

Transcanalicular laser-assisted dacryocystorhinostomy with diode laser.

This article compares the efficacy of transcanalicular laser assisted dacryocystorhinostomy (TL DCR) with conventional external dacryocystorhinostomy (Ex DCR). All patients were randomly divided into ...

Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative ataxia group, and tremor research group.

Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.

Medulloblastoma, the most common malignant pediatric brain tumor, is a heterogeneous disease, with the existence of at least four molecular types: Wingless (WNT), Sonic Hedgehog (SHH), Group 3 and Gro...

Application of the Pentafluorosulfanyl Group as a Bioisosteric Replacement.

The success of fluorinated molecules in drug design has led medicinal chemists to search for new fluorine-containing substituents. A major recently developed group is the pentafluorosulfanyl group. Th...

Systemic granulomatous disease in dairy cattle during a dicyandiamide feeding trial.

Mature, in-calf, non-lactating, Friesian or Friesian-cross cows were fed dicyandiamide (DCD) at daily doses of 0.15 g/kg (Group 1; n=31), 0.45 g/kg (Group 2; n=21) and 0.75 g/kg (Group 3; n=12), as pa...

Clinical Trials [3534 Associated Clinical Trials listed on BioPortfolio]

Ultra-wide Fluorescein Angiography in Patients With Central Retinal Vein Occlusion Treated by Afilbercept

In patients with macular edema secondary to CRVO, Aflibercept demonstrated efficacy and safety in 2 parallel trials, interventional phase III studies, COPERNICUS study performed in United ...

The Influence of Hypotensive Drugs on Mineral Status in Experimental and Clinical Studies

The aim of the study was to evaluate the effects of hypotensive treatment combined with a higher zinc supply in the diet and supplements on the mineral status and selected biochemical para...

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

The purpose of this study is to evaluate the safety and tolerability of single oral doses of TAK-828 in healthy non-Japanese and Japanese participants.

Technical Development of Multi-Parametric Renocerebral MRI

The purpose of the study is to investigate the associations of the age-related changes in the brain, kidneys and cognitive performance in healthy adults by utilizing multiple anatomic and ...

Electro-acupuncture and Flumazenil's Effect on Sedation

Object: To explore the mechanism of the electro-acupuncture (EA) induced sedation effect in general anaesthesia through investigating the role of the Benzodiazepines-GABA system. Method: ...

Companies [1600 Associated Companies listed on BioPortfolio]

Copernicus Group IRB

Copernicus Group IRB was established in July 1996 as an independent institutional review board (IRB or "Board") and operates in compliance with Federal Regulations governing institutional review board...

Copernicus Therapeutics Incorporated

Copernicus Therapeutics, Inc. is a privately-held company developing products for human gene therapy and vaccination. Copernicus was established in 1997 based on technologies discovered at Case Wester...

Copernicus Therapeutics, Inc.

Copernicus' Management and Board of Directors have experience in company management, pharmaceutical/biotechnology R&D, clinical development, and finance.

W2 Group, Inc.

W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital ...

PharmEvo (Pvt.) Ltd.

PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...

More Information about "Copernicus Group IRB" on BioPortfolio

We have published hundreds of Copernicus Group IRB news stories on BioPortfolio along with dozens of Copernicus Group IRB Clinical Trials and PubMed Articles about Copernicus Group IRB for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Copernicus Group IRB Companies in our database. You can also find out about relevant Copernicus Group IRB Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record